Literature DB >> 7768078

Sleep-inducing effects of low doses of melatonin ingested in the evening.

I V Zhdanova1, R J Wurtman, H J Lynch, J R Ives, A B Dollins, C Morabito, J K Matheson, D L Schomer.   

Abstract

We previously observed tht low oral doses of melatonin given at noon increase blood melatonin concentrations to those normally occurring nocturnally and facilitate sleep onset, as assessed using and involuntary muscle relaxation test. In this study we examined the induction of polysomnographically recorded sleep by similar doses given later in the evening, close to the times of endogenous melatonin release and habitual sleep onset. Volunteers received the hormone (oral doses of 0.3 or 1.0 mg) or placebo at 6, 8, or 9 PM. Latencies to sleep onset, to stage 2 sleep, and to rapid eye movement (REM) sleep were measured polysomnographically. Either dose given at any of the three time points decreased sleep onset latency and latency to stage 2 sleep. Melatonin did not suppress REM sleep or delay its onset. Most volunteers could clearly distinguish between the effects of melatonin and those of placebo when the hormone was tested at 6 or 8 PM. Neither melatonin dose induced "hangover" effects, as assessed with mood and performance tests administered on the morning after treatment. These data provide new evidence that nocturnal melatonin secretion may be involved in physiologic sleep onset and that exogenous melatonin may be useful in treating insomnia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768078     DOI: 10.1016/0009-9236(95)90040-3

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  38 in total

Review 1.  Melatonin and its receptors: a new class of sleep-promoting agents.

Authors:  Karl Doghramji
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

2.  Case-control study of evening melatonin concentration in primary insomnia.

Authors:  M E Attenburrow; B A Dowling; A L Sharpley; P J Cowen
Journal:  BMJ       Date:  1996-05-18

3.  Low dose melatonin improves sleep in healthy middle-aged subjects.

Authors:  M E Attenburrow; P J Cowen; A L Sharpley
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 4.  Circadian rhythms, athletic performance, and jet lag.

Authors:  R Manfredini; F Manfredini; C Fersini; F Conconi
Journal:  Br J Sports Med       Date:  1998-06       Impact factor: 13.800

5.  Daytime melatonin and temazepam in young adult humans: equivalent effects on sleep latency and body temperatures.

Authors:  S S Gilbert; C J van den Heuvel; D Dawson
Journal:  J Physiol       Date:  1999-02-01       Impact factor: 5.182

Review 6.  Melatonin, sleep, aging, and the health protection branch.

Authors:  S N Young
Journal:  J Psychiatry Neurosci       Date:  1996-05       Impact factor: 6.186

7.  A mathematical model of the circadian phase-shifting effects of exogenous melatonin.

Authors:  Emily R Breslow; Andrew J K Phillips; Jean M Huang; Melissa A St Hilaire; Elizabeth B Klerman
Journal:  J Biol Rhythms       Date:  2013-02       Impact factor: 3.182

Review 8.  Management of insomnia in patients with chronic pain conditions.

Authors:  Frederic Stiefel; Daniele Stagno
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease.

Authors:  Tharwat S Kandil; Amany A Mousa; Ahmed A El-Gendy; Amr M Abbas
Journal:  BMC Gastroenterol       Date:  2010-01-18       Impact factor: 3.067

Review 10.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.